前纵隔淋巴瘤与胸腺癌能谱CT的表现差异

马拓,曹立秀,李会菊,任红亮,陈大鹏,高媛,李志东,赵新斌,董思圻

中国医学科学院学报 ›› 2020, Vol. 42 ›› Issue (4) : 431-435.

PDF(952 KB)
PDF(952 KB)
中国医学科学院学报 ›› 2020, Vol. 42 ›› Issue (4) : 431-435. DOI: 10.3881/j.issn.1000-503X.11708
论著

前纵隔淋巴瘤与胸腺癌能谱CT的表现差异

作者信息 +

Different Energy Spectrum CT Findings between Anterior Mediastinal Lymphoma and Thymic Carcinoma

Author information +
文章历史 +

摘要

目的 探讨前纵隔淋巴瘤与胸腺癌能谱CT的表现差异。方法 选取唐山市人民医院穿刺活检病理证实的前纵隔淋巴瘤22例和胸腺癌28例,经能谱CT进行平扫和增强检查,应用能谱分析软件测量不同单能量下的CT值及病变部位的碘含量、水含量变化,比较前纵隔淋巴瘤和胸腺癌的差异。结果 胸腺癌动脉期和静脉期40~80 keV单能量CT值高于前纵隔淋巴瘤,差异有统计学意义(P=0.001,P=0.037,P=0.042,P=0.034,P=0.002;P=0.016,P=0.013,P=0.018,P=0.024,P=0.012);胸腺癌在90~110 keV单能量CT值与前纵隔淋巴瘤比较差异均无统计学意义(P均>0.05)。胸腺癌动脉期和静脉期水浓度低于前纵隔淋巴瘤,差异有统计学意义(P=0.030,P=0.037);碘浓度高于前纵隔淋巴瘤,差异有统计学意义(P=0.026,P=0.000)。结论 前纵隔淋巴瘤与胸腺癌在能谱CT检查40~80 keV单能量CT值及动脉期和静脉期水浓度、碘浓度上的差异显著,并可以此区分两者。

Abstract

Objective To investigate the differences in energy spectrum CT findings between anterior mediastinal lymphoma and thymic carcinoma. Methods Twenty-two cases of anterior mediastinal lymphoma and 28 cases of thymic carcinoma confirmed by biopsy in Tangshan People’s Hospital were selected.The CT values and changes of iodine content and water content in lesion sites were measured by energy spectrum analysis software.The differences between anterior mediastinal lymphoma and thymic carcinoma were compared. Results The single-energy CT value of 40-80 keV in thymus carcinoma was higher than that in anterior mediastinal lymphoma(P=0.001,P=0.037,P=0.042,P=0.034,P=0.002;P=0.016,P=0.013,P=0.018,P=0.024,P=0.012).The difference in the single-energy CT value of 90-110 keV between anterior mediastinal lymphoma and thymic carcinoma showed no statistical significance(all P>0.05).The concentrations of water in the arterial and venous stages of thymic carcinoma were significantly lower than those in the anterior mediastinal lymphoma(P=0.030,P=0.037),whereas the iodine concentrations were significantly higher(P=0.026,P=0.000). Conclusion Anterior mediastinal lymphoma and thymic carcinoma have remarkably different 40-80 keV single energy CT value and iodine concentration in arterial and venous phases,which may be helpful for the differential diagnosis of these two malignancies.

关键词

前纵隔 / 淋巴瘤 / 胸腺癌 / 体层摄影术

Key words

anterior mediastinal / lymphoma / thymic carcinoma / tomography

引用本文

导出引用
马拓 , 曹立秀 , 李会菊 , 任红亮 , 陈大鹏 , 高媛 , 李志东 , 赵新斌 , 董思圻. 前纵隔淋巴瘤与胸腺癌能谱CT的表现差异. 中国医学科学院学报. 2020, 42(4): 431-435 https://doi.org/10.3881/j.issn.1000-503X.11708
MA Tuo , CAO Lixiu , LI Huiju , REN Hongliang , CHEN Dapeng , GAO Yuan , LI Zhidong , ZHAO Xinbin , DONG Siqi. Different Energy Spectrum CT Findings between Anterior Mediastinal Lymphoma and Thymic Carcinoma. Acta Academiae Medicinae Sinicae. 2020, 42(4): 431-435 https://doi.org/10.3881/j.issn.1000-503X.11708
淋巴瘤和胸腺癌均属于纵隔恶性肿瘤,二者的临床及影像表现极为相似[1]。 治疗方法前者以放化疗为主,后者主要以手术切除为主,因此二者的鉴别尤为关键。能谱CT的开发是近年影像诊断领域的一项新突破。作为一种新兴的技术手段与方法,能谱CT在甲状腺良恶性结节[2]、肝硬化结节与癌性结节[3]及前列腺癌与前列腺增生结节鉴别诊断[4]等领域的应用正逐渐成为学科热点。基于此,本研究以能谱CT为技术手段,比较分析前纵隔淋巴瘤和胸腺癌各自的影像学特征,探讨前纵隔淋巴瘤与胸腺癌能谱CT的表现差异。

对象和方法

对象 选取 2017年9月至2018年10月于唐山市人民医院经穿刺活检病理证实的前纵隔淋巴瘤患者22例(前纵隔淋巴瘤组)和胸腺癌患者28例(胸腺癌组),经唐山市人民医院伦理委员会批准,研究对象均签署知情同意书。其中前纵隔淋巴瘤组男12例、女10例,平均年龄(51.43±10.16)岁;临床症状:咳嗽、胸前区不适12例,浅表淋巴结肿大7例,无明显症状3例。胸腺癌组男19例、女9例,平均年龄(52.52±9.84)岁;临床症状:胸痛、咳嗽、气喘18例,四肢无力6例,无明显症状4例。
方法 所有患者行能谱CT(GE Discovery CT 750 HD)检查,采用仰卧位,从胸廓入口平面扫描至双肺底,行常规平扫和能谱双期增强扫描。扫描速度0.6 s/周,螺距为0.984:1,平扫管电压120 kV;增强扫描管电压80 kV/140 kV快速切换。管电流为600 mA,层厚及层间距均5 mm。对比剂由高压注射器经肘前静脉团注,通常采用碘佛醇注射液(江苏恒瑞医药股份有限公司,200209DJ,320 mgI/ml),剂量1.0 ml/kg,流速3~4 ml/s,注射后25~30 s行单期增强扫描。
图像后处理 图像后处理与分析均在能谱分析软件AW 4.6工作站上进行。选取病变最大层面进行能谱分析,尽量避开囊变坏死、钙化及较大血管影。圆形感兴趣区放置病灶中央,其面积约90 mm2,保存相应数据文件。记录病灶在40~110 keV单能量的CT值及碘(水)浓度。
统计学处理 应用SPSS 20.0进行统计学分析。经检验计量资料CT值、水浓度、碘浓度均符合正态分布,采用配对t检验, P<0.05为差异有统计学意义。

结果

双期增强扫描前纵隔淋巴瘤和胸腺癌单能量CT值比较 胸腺癌动脉期和静脉期40~80 keV单能量CT值高于前纵隔淋巴瘤,差异有统计学意义(P=0.001,P=0.037,P=0.042,P=0.034,P=0.002;P=0.016,P=0.013,P=0.018,P=0.024,P=0.012);胸腺癌在90~110 keV单能量CT值与前纵隔淋巴瘤比较差异无统计学意义(表1、2,图1A、1B,图2A、2B)。
表1 动脉期增强扫描前纵隔淋巴瘤和胸腺癌单能量CT值比较(x̅±s,HU)

Table 1 Comparison of single energy CT values of mediastinal lymphoma and thymic carcinoma before arterial phase contrast-enhanced scanning(x̅±s,HU)

分组Group n 动脉期CT值 Arterial phase CT value
40 keV 50 keV 60 keV 70 keV 80 keV 90 keV 100 keV 110 keV
胸腺癌组
Thymic cancer group
22 86.34±7.51 74.42±6.83 66.45±5.86 55.37±4.15 46.25±4.06 42.71±3.83 35.56±2.82 28.46±1.76
淋巴瘤组
Lymphoma group
28 75.82±6.76 68.26±5.08 54.73±4.26 43.23±3.42 37.71±3.28 31.35±3.05 28.36±2.62 21.34±2.38
t 3.572 1.853 1.482 1.963 2.082 0.052 0.073 0.612
P 0.001 0.037 0.042 0.034 0.002 0.096 0.061 0.068
表2 静脉期增强扫描前纵隔淋巴瘤和胸腺癌单能量CT值比较(x̅±s,HU)

Table 2 Comparison of single energy CT values of mediastinal lymphoma and thymic carcinoma before intravenous phase contrast-enhanced scanning(x̅±s,HU)

分组Group n 静脉期CT值 Venous phase CT value
40 keV 50 keV 60 keV 70 keV 80 keV 90 keV 100 keV 110 keV
胸腺癌组
Thymic cancer group
22 132.53±23.48 103.48±18.64 83.42±8.62 75.58±6.75 68.49±6.27 56.86±5.45 48.32±4.18 36.73±3.43
淋巴瘤组
Lymphoma group
28 112.34±18.72 87.64± 9.56 69.45±7.37 58.41±6.62 51.46±5.24 47.26±4.43 41.64±3.68 29.25±2.49
t 2.372 2.385 2.156 1.766 2.631 0.073 0.084 0.093
P 0.016 0.013 0.018 0.024 0.012 0.082 0.075 0.057
图1 前纵隔淋巴瘤感兴趣区(圆圈L1)面积60.81 mm2
A.对应病灶动脉期70 keV纵隔窗图像;B.对应病灶静脉期70 keV纵隔窗图像;C.对应病灶动脉期水基图;D.对应病灶静脉期水基图;E.对应病灶动脉期碘基图;F.对应病灶静脉期碘基图

Fig 1 The area of interest of anterior mediastinal lymphoma(circle L1)is 60.81 mm2

A.the image of 70 keV corresponds to the arterial phase of the lesion;B.the image of 70 keV corresponds to the venous phase of the lesion;C.the image of water base of the arterial phase of the lesion;D.corresponds to the water base map of the focus vein phase;E.corresponds to the iodine base map of the focus artery phase;F.corresponds to the iodine base map of the focus vein phase

Full size|PPT slide

图2 胸腺癌感兴趣区(圆圈L2)面积56.33 mm2
A.对应病灶动脉期70 keV纵隔窗图像;B.对应病灶静脉期70 keV纵隔窗图像;C.对应病灶动脉期水基图;D.对应病灶静脉期水基图;E.对应病灶动脉期碘基图;F.对应病灶静脉期碘基图

Fig 2 The area of interest of thymic carcinoma(circle L2)is 56.33 mm2

A.the image of 70 keV corresponds to the arterial phase of the lesion;B.the image of 70 keV corresponds to the venous phase of the lesion;C.the image of water base of the arterial phase of the lesion;D.corresponds to the water base map of the focus vein phase;E.corresponds to the iodine base map of the focus artery phase;F.corresponds to the iodine base map of the focus vein phase

Full size|PPT slide

前纵隔淋巴瘤和胸腺癌水浓度和碘浓度的比较 胸腺癌动脉期和静脉期水浓度低于前纵隔淋巴瘤,差异有统计学意义(P=0.030,P=0.037);碘浓度高于前纵隔淋巴瘤,差异有统计学意义(P=0.026,P=0.000)(表3,图1C~1F,图2C~2F)。
表3 前纵隔淋巴瘤组和胸腺癌组水浓度和碘浓度的比较(x̅±s)

Table 3 Comparison of water concentration and iodine concentration between anterior mediastinal lymphoma group and thymic carcinoma group(x̅±s)

分组Group n 水浓度Water concentration(mg/cm3) 碘浓度Iodine concentration(μg/cm3)
动脉期Arterial phase 静脉期Venous phase 动脉期Arterial phase 静脉期Venous phase
胸腺癌组Thymic cancer group 22 1031.59±10.21 1026.01± 7.17 9.63±2.19 12.04±1.26
淋巴瘤组Lymphoma group 28 1046.37± 7.27 1040.39±10.65 6.69±1.01 7.33±0.87
t -2.636 -2.506 2.722 6.868
P 0.030 0.037 0.026 0.000

讨论

目前,临床普遍采用的普通CT扫描不仅能对纵隔病变进行准确定位,而且可以反映病变的血供,但对于前纵隔淋巴瘤和胸腺癌的鉴别仍有一定困难[5,6]。因为普通CT的球管产生连续混合能量分布的X线,所以获得的CT图像也具有混合能量的平均效应,不能形成平稳、准确的CT值 [7]。能谱CT是一种全新的成像技术,它可以对传统普通CT成像的原理进行分析,计算出各能量点处所吸收的X线,将传统CT的混合能量成像转换成为单能量的能谱成像[8,9],其采用高低能量瞬时切换,可以同时得到高(140 keV)、低(80 keV)两种能量X线的采样数据[10],并依据数据确定体素在40~110 keV能量内的衰减系数,获得101个单能量图像,进而直观地显示在40~110 keV下CT值的变化趋势[11]。这为两种疾病的鉴别诊断带来了新的方法和思路。
理论上两种组织相近似时,高能量的X射线能够穿过组织,而低能量的X射线可以引起明显的衰减差异,故可以利用这种衰减差异进行疾病的鉴别[12,13]。本研究显示胸腺癌动脉期和静脉期40~80 keV单能量CT值高于前纵隔淋巴瘤,差异有统计学意义;胸腺癌在90~110 keV单能量CT值与前纵隔淋巴瘤差别不大,无统计学意义。这可能是因为两种组织在特定的扫描能量中对X线的吸收不同所致。虽然两者均为软组织密度,在普通CT扫描时不能区分,但在能谱CT的某些单能量扫描下两者可能还是存在差别,这种衰减差异在某种程度上反映了病灶病例组织类型,原因在于组织来源、病变组织、化学性质等细微差异的不同。
增强扫描可以反映组织的血供情况。在普通CT的增强扫描时,前纵隔淋巴瘤与胸腺癌强化方式既存在差异有时表现又有重叠,即差异不足以准确区分两者。水和碘剂是能谱CT成像技术最常用的物质,由于碘基图对碘特别敏感,而对比剂中主要含碘,因此碘基图能够反映肿瘤的血供情况,并对其进行定量分析,准确显示病灶的强化程度[14]。本研究显示前纵隔淋巴瘤组在动脉期和静脉期的水浓度和碘浓度含量明显低于胸腺癌组,差异有统计学意义。这可能是因为前纵隔淋巴瘤和胸腺癌的组织来源、病理类型均不同,其引起的衰减差异同样可以导致水衰减的变化,且胸腺癌较前纵隔淋巴瘤具有更为丰富的血供,因此二者碘含量、水含量有所差异。
综上,前纵隔淋巴瘤与胸腺癌在能谱CT检查40~80 keV单能量CT值及动脉期和静脉期水浓度、碘浓度上的差异显著,并可以此区分两者。但考虑到样本容量较少,研究尚存在一定局限性。相信在今后大样本的支持下,会有更进一步的发现,为两者的影像鉴别诊断提供更重要的依据。

参考文献

[1]
Henschke CI, Lee IJ, Wu N, et al. CT screening for lung cancer:prevalence and incidence of mediastinal masses[J]. Radiology, 2006,239(2):586-590.DOI: 10.1148/radiol.2392050261.
PURPOSE: To determine the frequency and natural course of mediastinal masses in asymptomatic people at high risk for lung cancer who were undergoing computed tomographic (CT) screening. MATERIALS AND METHODS: Informed consent and institutional review board approval for this HIPAA-compliant study were obtained at each participating institution. All documented mediastinal masses among the 9263 baseline and 11 126 annual repeat screenings performed in the Early Lung Cancer Action Project (ELCAP) and its successor project, the New York ELCAP, were identified. Two radiologists confirmed all cases, identified the location and measured the diameter (average of length and width) of each mass, and reviewed all subsequent CT and clinical and surgical results. The prevalence and incidence of mediastinal masses were then determined. RESULTS: Of the 9263 individuals, 71 had a mediastinal mass seen at baseline screening (prevalence of 0.77%). Of the 71 masses, 41 were thymic, 16 were thyroidal, two were esophageal cancers, six were tracheal-esophageal diverticula, and six were other masses. Among the 11 126 annual repeat screenings, only one new mediastinal mass was identified (incidence of 0.01%). This suggests a long average duration for mediastinal masses in asymptomatic people. Among the 41 thymic masses, five were larger than 3.0 cm in diameter, and all five were resected; of these five, one was a thymic carcinoma and four were noninvasive thymomas. Of the remaining 36 thymic masses, 25 were evaluated at follow-up CT 1 year later: Five had increased in diameter, two had decreased, and 18 remained unchanged. All 16 thyroid masses were due to goiter; none of these were changed at follow-up CT 1 year later. CONCLUSION: Mediastinal masses found in the context of CT screening for lung cancer in asymptomatic people should be approached in a
[2]
李进叶, 宋歌声, 宋吉清, 等. 能谱CT与常规超声对甲状腺结节良恶性诊断价值的对照分析[J]. 山东大学学报:医学版, 2016,54(3):81-86.DOI: 10.6040/j.issn.1671-7554.0.2015.263.
[3]
Piscaglia F, Wilson SR, Lyshchik A, et al. American college of radiology contrast enhanced ultrasound liver imaging reporting and data system(CEUS LI-RADS)for the diagnosis of hepatocellular carcinoma:A pictorial essay[J]. Ultraschall Med, 2017,38(3):320-324.DOI: 10.1055/s-0042-124661.
[4]
Qi T, Chen Y, Zhu Y, et al. Contrast-enhanced transrectal ultrasonography for detection and localization of prostate index tumor:correlation with radical prostatectomy findings[J]. Urology, 2014,84(1):138-143.DOI: 10.1016/j.urology.2014.03.020.
OBJECTIVE: To evaluate the ability of contrast-enhanced transrectal ultrasonography (CETRUS) to detect and localize prostate index tumor. METHODS: Eighty-three patients with biopsy-proven prostate cancer (PCa), who were scheduled to undergo radical prostatectomy, were enrolled in this prospective study. Each patient underwent baseline grayscale and CETRUS imaging of the prostate according to a standardized protocol before the operation. Ultrasonography findings (CETRUS and grayscale imaging) were correlated with step-section histopathology. RESULTS: Overall, 53 and 68 tumor foci were detected by grayscale imaging and CETRUS, respectively. The combination of grayscale imaging and CETRUS allowed identification of 89 of the 232 cancer foci (38.4%). The sensitivity of combined imaging was significantly superior to that of grayscale imaging (P<.01) and CETRUS (P<.05). Additionally, the prostate index tumor detection rate by the use of grayscale imaging, CETRUS, and their combination was 42 of 83 (50.6%), 53 of 83 (63.9%), and 67 of 83 (80.7%), respectively. The combined approach performed significantly better than grayscale and CETRUS imaging (P<.001 and P<.05, respectively). The index tumor detection rate of CETRUS was higher than that of grayscale imaging, but no significant difference was found (P>.05). CONCLUSION: Our study has demonstrated significantly improved detection of both PCa and index tumor with a combined approach of CETRUS and grayscale imaging compared with baseline grayscale technique only, and this technique may be applicable to focal therapy of PCa.
[5]
张文浩, 叶丽芳, 雷永霞, 等. 纵隔淋巴瘤出现坏死的特点及相关因素分析[J]. 实用放射学杂志, 2014,30(8):1310-1312,1399.DOI: 10.3969/j.issn.1002-1671.2014.08.016.
[6]
Maren W, Rainer K, Michael D, et al. A Fastmagnetic resonance imaging technique for children with mediastinal lymphoma:work in progress[J]. Med Pediatr Oncol, 2001,37(2):532-536.DOI: 10.1002/mpo.1247.
[7]
彭杰, 王启伟, 李鹏, 等. 能谱CT去除冠状动脉钙化性斑块硬化伪影对心血管狭窄程度的诊断价值[J]. 生物医学工程与临床, 2018,14(2):45-48.DOI: 10.13339/j.cnki.sglc.20180313.011.
[8]
罗昆, 董仟, 杨明, 等. 双低对比剂联合能谱 CT 成像技术在门静脉成像中的应用研究[J]. 临床放射学杂志, 2016,35(11):1759-1763.DOI: 10.13437/j.cnki.jcr.2016.11.03.
[9]
张秋杭, 高艳, 李坤成, 等. 能谱CT GSI与MARS在减除脊柱金属植入物椎管内伪影效果的研究比较[J]. 临床放射学杂志, 2012,31(9):1338-1342.DOI: 10.13437/j.cnki.jcr.2012.09.011.
[10]
Fornaro J, Hibbeln D, Leschka S, et al. Dual-and multi-energy CT:Approach to functional imaging[J]. Insights Imaging, 2011,2(2):149-159.DOI: 10.1007/s13244-010-0057-0.
The energy spectrum of X-ray photons after passage through an absorber contains information about its elemental composition. Thus, tissue characterisation becomes feasible provided that absorption characteristics can be measured or differentiated. Dual-energy CT uses two X-ray spectra enabling material differentiation by analysing material-dependent photo-electric and Compton effects. Elemental concentrations can thereby be determined using three-material decomposition algorithms. In comparison to dual-energy CT used in clinical practice, recently developed energy-sensitive photon-counting detectors sample the material-specific attenuation curves at multiple energy levels and within narrow energy bands; the latter allows the detection of element-specific, k-edge discontinuities of the photo-electric cross section. Multi-energy CT imaging therefore is able to concurrently identify multiple materials with increased accuracy. These specific data on material distribution provide information beyond morphological CT, and approach functional imaging. This article reviews the principles of dual- and multi-energy CT imaging, hardware approaches and clinical applications.
[11]
Simons D, Kachelriess M, Schlemmer HP. Recent developments of dual-energy CT in oncology[J]. Eur Radiol, 2014,24(4):930-939.DOI: 10.1007/s00330-013-3087-4.
UNLABELLED: Dual-energy computed tomography (DECT) can amply contribute to support oncological imaging: the DECT technique offers promising clinical applications in oncological imaging for tumour detection and characterisation while concurrently reducing the radiation dose. Fast image acquisition at two different X-ray energies enables the determination of tissue- or material-specific features, the calculation of virtual unenhanced images and the quantification of contrast medium uptake; thus, tissue can be characterised and subsequently monitored for any changes during treatment. DECT is already widely used, but its potential in the context of oncological imaging has not been fully exploited yet. The technology is the subject of ongoing innovation and increasingly with respect to its clinical potential, particularly in oncology. This review highlights recent state-of-the-art DECT techniques with a strong emphasis on ongoing DECT developments relevant to oncologic imaging, and then focuses on clinical DECT applications, especially its prospective uses in areas of oncological imaging. KEY POINTS: * Dual-energy CT (DECT) offers fast, robust, quantitative and functional whole-body imaging. * DECT provides improved tumour detection and more detailed tissue differentiation and characterisation. * DECT affords therapy monitoring with complementary information and reduced radiation dose. * The use of DECT in oncology is of increasing clinical importance. * The potential of DECT in oncology has not been fully exploited yet.
[12]
Cheng J, Yin Y, Wu H, et al. Optimal monochromatic energy levels in spectral CT pulmonary angiography for the evaluation of pulmonary embolism[J]. PLoS One, 2013,8(23):e63140.DOI: 10.1371/journal.pone.0063140.
[13]
Kaufmann PA, Knuuti J. Ionizing radiation risks of cardiac imaging:estimates of the immeasurable[J]. Eur Heart J, 2011,32(14):269-271.DOI: 10.1093/eurheartj/ehq298.
[14]
黄仁军, 李勇刚. 能谱CT的临床应用与研究进展[J]. 放射学实践, 2015,30(1):81-83.DOI: 10.13609/j.cnki.1000-0313.2015.01.022.

基金

2019年度河北医学科学研究重点课题计划(20191622)

版权

版权所有,未经授权,不得转载、摘编本刊文章,不得使用本刊的版式设计。
PDF(952 KB)

372

Accesses

0

Citation

Detail

段落导航
相关文章

/